NeuroScientific Biopharmaceuticals Ltd. wishes to advise the resignation of both its Non-executive Chair Mr. Paul Rennie and Non-executive Director Mr. Stephen Quantrill. Both Paul and Stephen notified the Board on December 4, 2023, that they will be resigning from their positions with immediate effect, to focus on their other corporate commitments. The Board has appointed Chris Ntoumenopoulos as Non-executive Chair of the Company.

Additionally, the Board wishes to advise of the appointment of Anthony Keating as Non-executive Director, effective immediately. Dr Tony Keating is an experienced entrepreneur and CEO. Tony co-founded and led ResApp Health from start-up to $180M acquisition by Pfizer.

ResApp achieved CE marking as well as FDA and TGA approvals for its digital health products and secured partnerships with multiple biopharmaceutical and healthcare companies. Following ResApp's acquisition by Pfizer in 2022, Tony was a Vice President at Pfizer leading the integration of ResApp's business in Pfizer. Prior to co-founding ResApp, Tony was Director, Commercial Engagement at UniQuest where he led commercialisation of science-based technologies which included identification, development and funding of opportunities as well as sourcing and negotiating transactions with investors and strategic partners.

Tony holds a Doctor of Philosophy from The University of Queensland and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.